Systemic Anti-Inflammation
KPV & Larazotide
Lys-Pro-Val · AT-1001 · Mucosal Integrity Peptides
Two complementary peptides that address chronic oral inflammation at its molecular root — KPV targets the NF-κB inflammatory pathway, while Larazotide restores the mucosal barrier integrity that chronic inflammation and periodontal disease progressively erode.
What It Is & How It Works
What is KPV?
KPV (Lys-Pro-Val) is a C-terminal tripeptide of alpha-melanocyte-stimulating hormone with potent, selective anti-inflammatory activity mediated primarily through NF-κB pathway inhibition — reducing production of IL-1β, IL-6, TNF-α, and other cytokines that drive chronic oral inflammation.
What is Larazotide?
Larazotide acetate (AT-1001) is a tight-junction regulating peptide that strengthens epithelial barrier integrity across mucosal surfaces — including the oral epithelium. When the oral mucosal barrier is compromised, bacterial endotoxins from periodontal pathogens penetrate systemic circulation, driving systemic inflammation. Larazotide addresses this at its source.
Oral & gut-oral axis application
Together, KPV and Larazotide address the bidirectional gut-oral microbiome relationship. KPV is particularly relevant for refractory periodontitis, pericoronitis, chemotherapy-induced mucositis, or chronic gingival inflammation unresponsive to conventional scaling. Larazotide strengthens the mucosal defense layer that both systemic and oral inflammation erode over time.
Key Benefits
- Directly inhibits NF-κB — the master regulator of inflammatory gene expression — reducing cytokine burden in oral tissue
- Reduces IL-1β, IL-6, and TNF-α levels in inflamed gingival tissue
- Restores tight-junction barrier integrity in oral and GI mucosa
- Prevents bacterial endotoxin translocation from the oral cavity into systemic circulation
- Addresses refractory periodontitis and mucositis unresponsive to conventional treatment
- Supports the bidirectional gut-oral microbiome relationship
Key Benefits
Oral Capsule
Primary delivery for both peptides — designed for local mucosal action in the oral and GI tract · taken once or twice daily
Note: KPV and Larazotide are among the few peptides specifically designed for oral capsule delivery — their mechanism of action occurs locally along the oral-GI mucosal axis, making capsule the optimal and intended delivery route.
Possible Side Effects
- Mild GI discomfort (transient, typically resolves in week 1–2)
- Bloating or loose stools initially
- Rare: headache
- No systemic hormonal effects
Important Safety Profile
Both KPV and Larazotide have favorable safety profiles in clinical research. Larazotide has been studied in multiple human clinical trials for celiac disease with no serious adverse events. As these peptides act locally in the GI and oral tract, systemic side effect risk is minimal.
What to Expect
Measurable reduction in gingival inflammation is typically observed within 4–8 weeks when combined with professional periodontal care. Larazotide's barrier-restoration effects develop gradually as tight-junction proteins are upregulated. Your provider will assess treatment response at your 2-month follow-up appointment.
Regulatory Status
KPV and Larazotide are available as compounded peptide capsules through FDA-regulated compounding pharmacies, prescribed off-label for the indications described above. Larazotide has undergone Phase II and III human clinical trials for celiac disease. Your provider will review current status and provide complete informed consent.